# A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease

> **NCT06984627** · PHASE2 · RECRUITING · sponsor: **Sanofi** · enrollment: 30 (estimated)

## Conditions studied

- Graves' Disease

## Interventions

- **DRUG:** Rilzabrutinib dose 1
- **DRUG:** Rilzabrutinib dose 2

## Key facts

- **NCT ID:** NCT06984627
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-02
- **Primary completion:** 2026-08-25
- **Final completion:** 2026-09-23
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06984627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06984627, "A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06984627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*